Engraftment kinetics and transplant-related complications according to T-replete HLA-matched grafts and T-depleted HLA-mismatched grafts
| Transplant outcomes . | T-replete HLA-matched graft . | T-depleted HLA-mismatched graft (n = 47) . | P . | ||
|---|---|---|---|---|---|
| Marrow (n = 25) . | PBSC (n = 85) . | CB (n = 7) . | |||
| Engraftment kinetics | |||||
| Days to neutrophil recovery, median (range) | 22 (13-32) | 15 (6-40) | 27 (17-33) | 14 (0-27) | <.001 |
| Days to platelet recovery, median (range) | 19.5 (7-103) | 15 (3-66) | 27 (17-41) | 15 (6-90) | .002 |
| aGvHD, % (95% CI) | |||||
| 1-year CIN grade II-IV aGvHD | 18 (7-48) | 26 (16-41) | 14 (2-79) | 18 (9-39) | NS |
| 1-year CIN grade III-IV aGvHD | 8 (2-3) | 7 (3-17) | 14 (2-79) | 2 (3-17) | NS |
| Organ involved in aGvHD (all stages), n (%) | |||||
| Skin | 6 (24) | 28 (33) | 2 (29) | 17 (36) | NS |
| Gut | 0 | 2 (2) | 1 (14) | 1 (2) | NS |
| Liver | 0 | 2 (2) | 0 | 0 | — |
| Chronic GvHD, n (%) | 0 | 0 | 0 | 0 | — |
| New onset of viremia after HCT, n (%) | |||||
| CMV viremia | 6 (24) | 17 (20) | 0 | 14 (30) | NS |
| Adenoviremia | 5 (20) | 19 (22) | 0 | 22 (47) | .004 |
| HHV6 viremia | 4 (16) | 24 (28) | 0 | 24 (51) | .002 |
| EBV viremia | 5 (20) | 11 (13) | 1 (14) | 8 (17) | NS |
| TMA, n (%) | 0 | 4 (5) | 1 (14) | 4 (9) | .33 |
| Acute kidney injury, n (%) | 16 (64) | 57 (67) | 2 (28) | 11 (23) | <.001 |
| Graft failure, n (%) | 0 | 4 (5) | 0 | 2 (4) | NS |
| No. of deaths, n (%) | 1 (4) | 9 (10) | 1 (14) | 8 (17) | NS |
| Cause of death | |||||
| GvHD | 0 | 1 | 0 | 0 | |
| Multiorgan failure | 1 | 2 | 0 | 3 | |
| Infection | 0 | 3 | 0 | 3 | |
| Others | 0 | 3* | 1† | 2‡ | |
| Transplant outcomes . | T-replete HLA-matched graft . | T-depleted HLA-mismatched graft (n = 47) . | P . | ||
|---|---|---|---|---|---|
| Marrow (n = 25) . | PBSC (n = 85) . | CB (n = 7) . | |||
| Engraftment kinetics | |||||
| Days to neutrophil recovery, median (range) | 22 (13-32) | 15 (6-40) | 27 (17-33) | 14 (0-27) | <.001 |
| Days to platelet recovery, median (range) | 19.5 (7-103) | 15 (3-66) | 27 (17-41) | 15 (6-90) | .002 |
| aGvHD, % (95% CI) | |||||
| 1-year CIN grade II-IV aGvHD | 18 (7-48) | 26 (16-41) | 14 (2-79) | 18 (9-39) | NS |
| 1-year CIN grade III-IV aGvHD | 8 (2-3) | 7 (3-17) | 14 (2-79) | 2 (3-17) | NS |
| Organ involved in aGvHD (all stages), n (%) | |||||
| Skin | 6 (24) | 28 (33) | 2 (29) | 17 (36) | NS |
| Gut | 0 | 2 (2) | 1 (14) | 1 (2) | NS |
| Liver | 0 | 2 (2) | 0 | 0 | — |
| Chronic GvHD, n (%) | 0 | 0 | 0 | 0 | — |
| New onset of viremia after HCT, n (%) | |||||
| CMV viremia | 6 (24) | 17 (20) | 0 | 14 (30) | NS |
| Adenoviremia | 5 (20) | 19 (22) | 0 | 22 (47) | .004 |
| HHV6 viremia | 4 (16) | 24 (28) | 0 | 24 (51) | .002 |
| EBV viremia | 5 (20) | 11 (13) | 1 (14) | 8 (17) | NS |
| TMA, n (%) | 0 | 4 (5) | 1 (14) | 4 (9) | .33 |
| Acute kidney injury, n (%) | 16 (64) | 57 (67) | 2 (28) | 11 (23) | <.001 |
| Graft failure, n (%) | 0 | 4 (5) | 0 | 2 (4) | NS |
| No. of deaths, n (%) | 1 (4) | 9 (10) | 1 (14) | 8 (17) | NS |
| Cause of death | |||||
| GvHD | 0 | 1 | 0 | 0 | |
| Multiorgan failure | 1 | 2 | 0 | 3 | |
| Infection | 0 | 3 | 0 | 3 | |
| Others | 0 | 3* | 1† | 2‡ | |